Onslaught of new drugs will shake up MS, diabetes, cancer and more

Tracy Staton A bumper crop of FDA approvals in 2015 means an equal number of launches to keep an eye on in 2016. Last year, FiercePharmaMarketing brought you a list of 8 markets to ...

IPOs: The chill finally set in, so when’s the rally?

John Carroll ​Last year at this time I ended up predicting that we'd see things cool down on the IPO side. Going into the third year of a biotechapalooza of initial public offerings ...

Think different? Pharma turns to tech partnerships for beyond-the-pill moves

Tracy Staton There's not going to be a beyond-the-pill revolution in 2016. Frankly, pharma doesn't yet have the technology to move beyond pushing products to delivering outcomes. ...

Pricing pressure: Doubling down on the political drama

John Carroll ​With all the brouhaha over Martin Shkreli's 5000%-plus price hike, it's important to remember what got us to this point on drug pricing and where we're left ...

What’s the calendar bringing biopharma next year? Our top 5 ideas

Tracy Staton Winter days are short and dark. December is winding down. If you're not already on a holiday break, you likely will be soon. So, it's a good time to take a minute ...

Shkreli charges prompt Nasdaq to delist KaloBios

Carly Helfand Martin Shkreli has already been ousted as CEO of KaloBios. And now, Nasdaq plans to delist the company, citing Shkreli's recent arrest on fraud and looting charges ...

Globalization: Another year closer to a worldwide network

John Carroll When AstraZeneca announced its move to create its third R&D hub in China, the pharma giant was following in the paths of some major rivals. It also represented another ...

M&A: Buckle your seat belts for another big round of deals

John Carroll With valuations down, buyouts and licensing deals become even more attractive. They're already a requirement. Anyone with a casual acquaintance with the state of Big ...

Think we’ve seen the last of pharma’s M&A tidal wave? Think again

Carly Helfand If you think 2015 was a big year in pharma M&A, just wait. That train won't be slowing down any time soon, industry watchers say. On the contrary, they're ...

The top biopharma trends for 2016

John Carroll Look back on 2015 and you'll see an industry that has come into its own. With billions of dollars flowing in from IPOs, follow-ons, venture investors, the rich (those ...

Brace yourselves: The drug pricing brouhaha isn’t dying down

Tracy Staton Drug prices were already a sore subject, but the pain grew this fall, when the now-former CEO of Turing Pharmaceuticals Martin Shkreli unapologetically jacked up the price ...

VCs: Venture funding grows, with more money for startups

John Carroll That IPO boom was just what the VC doctor ordered. Between high-priced buyout deals and new offerings, the venture funds got the exits they needed to look good to investors ...
Page 2 of 712345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS